Skip to main
PVLA

PVLA Stock Forecast & Price Target

PVLA Analyst Ratings

Based on 15 analyst ratings
Strong Buy
Strong Buy 73%
Buy 27%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Palvella Therapeutics Inc demonstrates a promising outlook based on data indicating an average potential share price increase of 168% across various scenarios. The successful clinical trial results for QTORIN rapamycin show significant improvements on key endpoints, including a 3.36-point enhancement in the mLM multi-component static scale, which could lead to increased compliance due to substantial symptom relief in patients. Furthermore, the positive results from clinician and patient-reported outcome measures support the potential for favorable acceptance among prescribers and payors, reinforcing the company's strategic position in the market for rare genetic skin diseases.

Bears say

Palvella Therapeutics faces significant financial challenges that contribute to a negative outlook on its stock. The potential for lower-than-projected pricing for QTORIN rapamycin could substantially diminish its commercial viability, even with regulatory approval, compounded by the uncertainty surrounding patient access and onboarding, which might hamper long-term market penetration. Furthermore, the company may require additional capital, potentially through equity financing, leading to share dilution for existing shareholders before achieving profitability.

PVLA has been analyzed by 15 analysts, with a consensus rating of Strong Buy. 73% of analysts recommend a Strong Buy, 27% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Palvella Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Palvella Therapeutics Inc (PVLA) Forecast

Analysts have given PVLA a Strong Buy based on their latest research and market trends.

According to 15 analysts, PVLA has a Strong Buy consensus rating as of Mar 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $169.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $169.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Palvella Therapeutics Inc (PVLA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.